UW Research

Master Clinical Trial Agreements

The Office of Sponsored Programs has Master Clinical Trial/Study & Confidentiality Agreements with many companies and Contract Research Organizations (CRO).

Master Clinical Trial Agreement – Companies Expiration
Abbvie Inc. July 12, 2028
Abiomed None
Actelion None
Activbiotics None
Alkermes, Inc. September 23, 2026
Amgen None
Aragon None
Astellas Under neg.
AstraZeneca None
Bayer Corporation None
Biogen Idec None
Boehringer Ingelheim Pharma April 19, 2028
Bristol Myers Squibb January 19, 2025
Bristol Myers Squibb Medical Imaging None
Clovis None
Cochlear Americas None
Edwards Lifesciences, LLC None
Eli Lilly and Company None
EMD Serono, Inc. None
Fred Hutchinson Incoming Subcontract Form None
General Electric Co. (Comp. Research) None
Genzyme Corporation None
Hamilton Health Sciences
(Coordinating Agreement)
None
Hoffman-LaRoche, Inc. None
Hoosier Oncology None
Intermune None
Jaeb Center for Health Research DRC December 31, 2024
Janssen Research & Development, LLC December 7, 2026
Medtronic, Inc. May 12, 2026
Merck None
Millennium Pharmaceuticals None
Novartis Pharmaceuticals Corp. April 20, 2029
Pfizer March 1, 2024
Pharmacyclics, Inc. None
Renal Cancer Clinical Trial Consortium None
Roche Laboratories None
Sanofi-Aventis March 6, 2025
SC Liver Research Consortium  None
Seattle Genetics January 31, 2025
Vertex None

Prostate Cancer Clinical Trial Consortium Master Clinical Trial Agreements (CTA)

The following Master CTAs are through the Prostate Cancer Clinical Trial Consortium, and for members only.

Prostate Cancer Clinical Trial Consortium – Master CTAs Expiration
Aragon None
Algeta ASA None
BMS (PI-initiated trials only) None
Hollis-Eden None
ImaginAb, Inc. None
Kinex Pharmaceuticals None
Medivation None
Sanofi None

Master Confidentiality Agreements (CDAs)

Master CDAs – Companies Expiration
AbbVie
Alkermes None
Alpine
AstraZeneca None
Merck
Sanofi None